Breast lesions detected by MRI and classified as BI-RADS 2 were shown to not be malignant, and therefore do not need biopsy.
Breast biopsies are unnecessary for breast lesions found by breast MRI and characterized as BI-RADS 2, according to a study published in the journal Clinical Radiology.
Researchers from Austria performed a retrospective single-center study to assess the frequency of malignancies in lesions characterized as benign on breast MRI.
A total of 1,265 patients, mean age 50, were included in the study. All had undergone dynamic contrast-enhanced MRI (1.5 T) of the breast during a six-year period.
The researchers examined the MRI characteristics and frequency of malignancy in 192 of the patients found to have breast lesions classified as BI-RADS 2.
The lesions were either histopathologically verified or subjected to both clinical and imaging follow-up of at least two years (range: two to nine years).
The results showed that no lesions that were classified as BI-RADS 2 were found to be malignant. “Histopathology was available in 67 (34.9%) lesions and revealed benign findings exclusively,” the authors wrote. “The remaining 125 (65.1%) lesions did not exhibit changes during the follow-up period and were, therefore, considered negative for malignancy.”
The researchers concluded that breast biopsies are unnecessary for breast lesions classified as BI-RADS 2, due to the absence of malignancies.
MRI Study Suggests Shape of White Matter Hyperintensities May Be Predictive of Cognitive Decline
April 7th 2025Emerging research demonstrated that cognitive declines in memory, executive function and processing speed domains were associated with irregular shape of periventricular/confluent white matter hyperintensities.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.